- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- ecallantide
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 39
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 35 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,189
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure
- Interventions
- Not listed
- Lead sponsor
- ELA Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 33
- States / cities
- Mesa, Arizona • Beverly Hills, California • Encino, California + 26 more
- Conditions
- HIV, Infectious
- Interventions
- darunavir, ritonavir
- Drug
- Lead sponsor
- Tibotec, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 38 more
- Conditions
- Prostate Cancer
- Interventions
- Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide
- Drug · Radiation
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 11
- States / cities
- Stamford, Connecticut • Boston, Massachusetts • Milford, Massachusetts + 6 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage I Ovarian Cancer AJCC v8, Stage IA Ovarian Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage IB Ovarian Cancer AJCC v8, Stage IC Ovarian Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIA Ovarian Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIB Ovarian Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8
- Interventions
- Chemotherapy, Functional Assessment, Questionnaire Administration
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 166
- States / cities
- Antioch, California • Dublin, California • Fremont, California + 132 more
- Conditions
- Breast Neoplasm, Neoplasm Metastasis
- Interventions
- Abemaciclib, Fulvestrant, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Fullerton, California + 52 more
- Conditions
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Sunitinib Malate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 484
- States / cities
- Anniston, Alabama • Mobile, Alabama • Little Rock, Arkansas + 321 more
- Conditions
- Abdominal Aortic Aneurysms, Iliac Aneurysms, Aortoiliac Aneurysms
- Interventions
- Zenith Low Profile AAA Endovascular Graft and ancillary components
- Device
- Lead sponsor
- Cook Research Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 36
- States / cities
- Stanford, California • Aurora, Colorado • Hartford, Connecticut + 32 more
- Conditions
- Hepatitis B, Liver Transplantation
- Interventions
- HepaGam B
- Biological
- Lead sponsor
- Cangene Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 9 more
- Conditions
- Neuroblastoma
- Interventions
- carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, Isotretinoin, Surgery, Filgrastim
- Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 12 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2021
- U.S. locations
- 166
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 137 more
- Conditions
- Tinea Pedis
- Interventions
- Experimental Drug SESC 01, Placebo, Terbinafine Hydrochloride
- Drug
- Lead sponsor
- South End Skin Care
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Milford, Massachusetts
- Conditions
- HIV Infection
- Interventions
- All licensed antiretroviral medications
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,688 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 55
- States / cities
- Alhambra, California • Los Angeles, California • San Diego, California + 37 more
- Conditions
- Healthy Participants
- Interventions
- REGN10933 + REGN10987, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Day and older
- Enrollment
- 3,303 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 132
- States / cities
- Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more
- Conditions
- FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 25 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1083
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more
- Conditions
- Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
- Radiation · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 9 Years
- Enrollment
- 5,377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2021
- U.S. locations
- 210
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
- Conditions
- Hypertension, Pulmonary
- Interventions
- Riociguat (Adempas, BAY63-2521)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 58
- States / cities
- Tucson, Arizona • La Jolla, California • Moreno Valley, California + 51 more
- Conditions
- Overt Hepatic Encephalopathy
- Interventions
- 40 mg Rifaximin SSD once daily, 40 mg Rifaximin SSD twice daily, 80 mg Rifaximin SSD once daily, 80 mg Rifaximin SSD twice daily, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 34
- States / cities
- Corona del Mar, California • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
- Interventions
- Lorcaserin hydrochloride, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 14,673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 373
- States / cities
- Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more
- Conditions
- Colorectal Cancer
- Interventions
- cetuximab, irinotecan hydrochloride, vemurafenib
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 763
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 489 more
- Conditions
- Desmoplastic/Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma With Extensive Nodularity, Nevoid Basal Cell Carcinoma Syndrome
- Interventions
- Carboplatin, Cognitive Assessment, Cyclophosphamide, Etoposide, Laboratory Biomarker Analysis, Methotrexate, Vincristine Sulfate
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 47 Months
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 158
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 126 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Veligrotug
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Inglewood, California • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- IDEA-033
- Drug
- Lead sponsor
- IDEA AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 875 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Northport, Alabama + 86 more
- Conditions
- Breast Cancer
- Interventions
- Bevacizumab, Cyclophosphamide, Methotrexate, Lifestyle: Diet, Lifestyle: Diet+Exercise
- Drug · Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • Boston, Massachusetts + 5 more
- Conditions
- Heart Transplant
- Interventions
- Heart transplant
- Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 10 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 12
- States / cities
- San Francisco, California • Chicago, Illinois • Maywood, Illinois + 7 more